Tousignant C, Regoli D, Rhaleb N E, Jukic D, Guillemette G
Department of Pharmacology, Faculty of Medicine, University of Sherbrooke, Que., Canada.
Eur J Pharmacol. 1992 Mar 12;225(3):235-44. doi: 10.1016/0922-4106(92)90025-q.
We have recently shown that (a) [125I-Tyr8]bradykinin (BK) recognized bradykinin binding sites in guinea pig epithelium membranes with a Kd value of 1.6 nM and a Bmax of 156 fmol/mg protein, and (b) B2 agonists and some B2 antagonists, such as D-Arg-[Hyp3,D-Phe7,Leu8]BK, inhibited this specific binding with a Ki value of 32 nM. In the present study, we have radioiodinated the B2 antagonist Tyr-D-Arg-[Hyp3,D-Phe7,Leu8]BK and have performed a full characterization of the binding properties of this tracer in the same membrane preparation. Equilibrium experiments performed in the absence or presence of an excess of BK (10(-5) M) showed that 125I-Tyr-D-Arg-[Hyp3,D-Phe7,Leu8]BK specifically labelled two different sites. One of these is the same as the site labelled by [125I-Tyr8]BK, and this indicates that 125I-Tyr-D-Arg-[Hyp3,D-Phe7,Leu8]BK interacts specifically with kinin B2 receptors. Equilibrium experiment performed in the presence of an excess of BK (10(-5) M) indicated that specific binding of 125I-Tyr-D-Arg-[Hyp3,D-Phe7,Leu8]BK to the second site is also saturable and Scatchard analysis showed that the site is of high affinity with a Kd of 16.8 nM and a Bmax of 2.08 pmol/mg protein. Surprisingly, unlabelled B2 agonists such as bradykinin, [Tyr8]BK, [Leu8]BK, [Hyp3,Tyr8(OMe)]BK, D-Arg-[Hyp3]BK and kallidin were found to be inactive on this second site. A series of B2 receptor antagonists, Tyr-D-Arg-[Hyp3,D-Phe7,Leu8]BK, D-Arg-[Hyp3,D-Phe7,Leu8]BK, D-Arg-[Hyp3,Leu5,8,D-Phe7]BK, D-Arg-[Hyp3,Gly6,D-Phe7,Leu8]BK and D-Arg-[Hyp3,Thi5,8,D-Phe7]BK inhibited 125I-Tyr-D-Arg-[Hyp3,D-Phe7,Leu8]BK binding with Ki values of 25.0, 20.9, 15.8, 64.6 and 6606.9 nM respectively. On the other hand, [Thi5,8,D-Phe7]BK did not interfere with 125I-Tyr-D-Arg-[Hyp3,D-Phe7,Leu8]BK but was found to be a potent inhibitor of [125I-Tyr8]BK binding (Ki = 53.7 nM). As expected, B1 receptor agonists, antagonists and peptides non-related to BK such as substance P, neurokinin A, neurokinin B, angiotensin II, bombesin, vasopressin and the calcitonin gene related peptide were unable to compete with 125I-Tyr-D-Arg-[Hyp3,D-Phe7,Leu8]BK. The results show that 125I-Tyr-D-Arg-[Hyp3,D-Phe7,Leu8]BK is interacting with two distinct binding sites in the guinea pig epithelium: one is the well known bradykinin B2 receptor and the other is a new, non-characterized binding site that interacts exclusively with some bradykinin receptor antagonists.
(a) [125I - Tyr8]缓激肽(BK)可识别豚鼠上皮细胞膜中的缓激肽结合位点,其解离常数(Kd)值为1.6 nM,最大结合量(Bmax)为156 fmol/mg蛋白质;(b) B2激动剂和一些B2拮抗剂,如D - Arg - [Hyp3,D - Phe7,Leu8]BK,可抑制这种特异性结合,其抑制常数(Ki)值为32 nM。在本研究中,我们对B2拮抗剂Tyr - D - Arg - [Hyp3,D - Phe7,Leu8]BK进行了放射性碘化,并在相同的膜制剂中对该示踪剂的结合特性进行了全面表征。在不存在或存在过量BK(10^(-5) M)的情况下进行的平衡实验表明,125I - Tyr - D - Arg - [Hyp3,D - Phe7,Leu8]BK特异性标记了两个不同的位点。其中一个位点与[125I - Tyr8]BK标记的位点相同,这表明125I - Tyr - D - Arg - [Hyp3,D - Phe7,Leu8]BK与激肽B2受体特异性相互作用。在存在过量BK(10^(-5) M)的情况下进行的平衡实验表明,125I - Tyr - D - Arg - [Hyp3,D - Phe7,Leu8]BK与第二个位点的特异性结合也是可饱和的,Scatchard分析表明该位点具有高亲和力,Kd为16.8 nM,Bmax为2.08 pmol/mg蛋白质。令人惊讶的是,未标记的B2激动剂,如缓激肽、[Tyr8]BK、[Leu8]BK、[Hyp3,Tyr8(OMe)]BK、D - Arg - [Hyp3]BK和胰激肽,在这个第二位点上没有活性。一系列B2受体拮抗剂,Tyr - D - Arg - [Hyp3,D - Phe7,Leu8]BK、D - Arg - [Hyp3,D - Phe7,Leu8]BK、D - Arg - [Hyp3,Leu5,8,D - Phe7]BK、D - Arg - [Hyp3,Gly6,D - Phe7,Leu8]BK和D - Arg - [Hyp3,Thi5,8,D - Phe7]BK抑制125I - Tyr - D - Arg - [Hyp3,D - Phe7,Leu8]BK结合的Ki值分别为25.0、20.9、15.8、64.6和6606.9 nM。另一方面,[Thi5,8,D - Phe7]BK不干扰125I - Tyr - D - Arg - [Hyp3,D - Phe7,Leu8]BK,但被发现是[125I - Tyr8]BK结合的有效抑制剂(Ki = 53.7 nM)。正如预期的那样,B1受体激动剂、拮抗剂以及与BK无关的肽,如P物质、神经激肽A、神经激肽B、血管紧张素II、蛙皮素、加压素和降钙素基因相关肽,均不能与125I - Tyr - D - Arg - [Hyp3,D - Phe7,Leu8]BK竞争。结果表明,125I - Tyr - D - Arg - [Hyp3,D - Phe7,Leu8]BK与豚鼠上皮中的两个不同结合位点相互作用:一个是众所周知的缓激肽B2受体,另一个是新的、未表征的结合位点,该位点仅与一些缓激肽受体拮抗剂相互作用。